- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Tuesday, 08 December 2009
-
Current Status:
Answered by Shona Robison on 22 December 2009
To ask the Scottish Executive what its most recent estimated cost to date is of the multiple sclerosis risk-sharing scheme and what it estimates will be the total cost of the scheme over its projected lifespan.
Answer
The multiple sclerosis risk-sharing scheme applies across the UK. Since the scheme began in May 2002 it is estimated that the total UK costs incurred have been around £350 million. The costs associated with the scheme are comprised of drug costs, administration costs and the UK health departments'' share of the costs of running the contract. Drug costs, which are the main component of overall costs, are estimated to be in the region of £50 million per year.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Tuesday, 08 December 2009
-
Current Status:
Answered by Shona Robison on 22 December 2009
To ask the Scottish Executive what recent assessment it has made of the operation of the multiple sclerosis risk-sharing scheme.
Answer
The multiple sclerosis risk-sharing scheme has allowed around 12,000 across the UK to be treated under the scheme. Over 5,500 patients are routinely monitored to assess their progress on treatment. The first two-year analysis of scheme data has been undertaken and has been published on the British Medical Journal website. This information can be accessed at:
http://www.bmj.com/cgi/content/full/339/dec02_1/b4677.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Monday, 07 December 2009
-
Current Status:
Answered by Nicola Sturgeon on 22 December 2009
To ask the Scottish Executive what action it is taking to reduce healthcare associated infections in community healthcare settings.
Answer
The three-year HAI (healthcare associated infection) task force delivery plan has a specific action (action 1.10) to tackle infections associated with the community healthcare setting. The delivery plan is at
http://www.scotland.gov.uk/Publications/2008/03/07110818/0.
Work to-date includes the publication of Infection Prevention and Control Guidance for NHS and non-NHS Community and Primary Care Settings, which was published on the Health Protection Scotland (HPS) website in July 2009, and a poster detailing the standard infection control precautions that should be followed in community and primary care settings.
The link to the guidance is:
http://www.documents.hps.scot.nhs.uk/hai/infection-control/publications/chp-g-2009-07-31.pdf.
The link to the poster is:
http://www.documents.hps.scot.nhs.uk/hai/infection-control/publications/community-sicp-poster.pdf.
It is also the case that the revised NHS Quality Improvement Scotland (NHS QIS) healthcare associated infection standards are applied to all health care settings to assess both organisational structures and the delivery of HAI policies.
The link to the HAI Standards is http://www.nhshealthquality.org/nhsqis/4099.html.
The Scottish Government also provides funding to the care commission to support a nurse consultant for healthcare associated infection in day care for children''s services and care homes for older people in Scotland.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Tuesday, 08 December 2009
-
Current Status:
Answered by Shona Robison on 22 December 2009
To ask the Scottish Executive what assessment it has made of the progress of the multiple sclerosis risk-sharing scheme.
Answer
The UK multiple sclerosis risk-sharing scheme for beta interferon and glatiramer acetate allows these treatments to be prescribed on the NHS in accordance with guidelines developed by the Association of British Neurologists. Around 12,000 patients across the UK are being treated under the scheme. Under the terms of the scheme a cohort of over 5,500 patients are monitored to assess their progress on treatment. The first two-year analysis of scheme data has been undertaken and has been published on the British Medical Journal website. This information can be accessed at:
http://www.bmj.com/cgi/content/full/339/dec02_1/b4677.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Monday, 07 December 2009
-
Current Status:
Answered by Shona Robison on 21 December 2009
To ask the Scottish Executive what estimate it has made of the cost of obesity to the NHS and how this cost has changed over the last 10 years.
Answer
We will publish our most recent analysis of the cost of obesity to the NHS in the next few weeks.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Monday, 07 December 2009
-
Current Status:
Answered by Shona Robison on 21 December 2009
To ask the Scottish Executive what estimate it has made of the cost to the NHS of treating obesity-related illness and how this cost has changed over the last 10 years.
Answer
We will publish our most recent analysis of the cost of obesity to the NHS including treating obesity-related illness in the next few weeks.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Thursday, 03 December 2009
-
Current Status:
Answered by Shona Robison on 15 December 2009
To ask the Scottish Executive how many prescriptions for natalizumab, brand name Tysabri, have been dispensed in each of the last two years, broken down by NHS board.
Answer
This information is not available.
Natalizumab (Tysabri®) therapy should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of neurological conditions, in centres with timely access to MRI. It is administered by intravenous infusion in an outpatient clinic setting with resources for the management of hypersensitivity reactions.
Prescription data collected centrally relate to prescribed items dispensed in the community by community pharmacists and dispensing doctors.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Wednesday, 25 November 2009
-
Current Status:
Answered by Shona Robison on 7 December 2009
To ask the Scottish Executive how many babies were born at the Inverclyde Royal Hospital Community Maternity Unit in each of the last three years.
Answer
The number of babies born in the Inverclyde Royal Hospital is set out in the following table:
As in other statistics published by the General Register Office for Scotland (GROS), each birth is counted on the basis of the year in which it was registered, which may not be the same as the year in which it occurred.
Provisional figures for 2009 will not be available until March 2010
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Wednesday, 25 November 2009
-
Current Status:
Answered by Shona Robison on 7 December 2009
To ask the Scottish Executive how many babies were born between the hours of 9 am and 5 pm at the Inverclyde Royal Hospital Community Maternity Unit in each of the last three years.
Answer
The number of babies born between the hours of 9 am and 5 pm in the Inverclyde Royal Hospital is set out in the following table:
As in other statistics published by the General Register Office for Scotland (GROS), each birth is counted on the basis of the year in which it was registered, which may not be the same as the year in which it occurred.
Provisional figures for 2009 will not be available until March 2010.
- Asked by: Ross Finnie, MSP for West of Scotland, Scottish Liberal Democrats
-
Date lodged: Wednesday, 25 November 2009
-
Current Status:
Answered by Nicola Sturgeon on 4 December 2009
To ask the Scottish Executive whether funding for additional staff is being made available to NHS boards to provide backfill for district nurses administering the influenza A (H1N1) vaccine to housebound patients.
Answer
No extra funding has been provided to NHS boards for additional staff.
However, the Scottish Government has offered to meet the re-registration costs of nurses returning to the NHS during this pandemic to support the delivery of services.